Etidronic acid
- Generic Name
- Etidronic acid
- Drug Type
- Small Molecule
- Chemical Formula
- C2H8O7P2
- CAS Number
- 2809-21-4
- Unique Ingredient Identifier
- M2F465ROXU
- Background
Etidronic acid is a first generation bisphosphonate similar to clodronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate zoledronic acid, ibandronic acid, minodronic acid, and risedronic acid.
Etidronic acid was granted FDA approval on 1 September 1977.
- Indication
Etidronate is indicated to treat Paget's disease of bone, as well as the treatment and prevention of heterotropic ossification after total hip replacement of spinal cord injury.
- Associated Conditions
- Heterotopic Ossification (HO), Paget's Disease of Bone
The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 76
- Registration Number
- NCT05832580
- Locations
- 🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome
- Conditions
- Fahr DiseaseFahr SyndromePrimary Familial Brain Calcification
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 98
- Registration Number
- NCT05662111
- Locations
- 🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands
Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)
- Conditions
- Arterial CalcificationCD73 Deficiency
- Interventions
- Device: MRI Scan
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2022-10-04
- Target Recruit Count
- 7
- Registration Number
- NCT01585402
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
- Conditions
- AdenocarcinomaEsophageal CancerSquamous Cell Carcinoma
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 684815
- Registration Number
- NCT01077817
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.